MetaVia stock analysis
Want to see MTVA full AI Analyst Report?
MetaVia (MTVA) Stock Price & Analysis
MTVA Stock Chart & Stats
- Day’s Range
- $1.25 - $1.43
- 52-Week Range
- $0.97 - $13.42
- Previous Close
- $1.30
- Volume
- N/A
- Average Volume (3M)
- 149.35K
- Market Cap
- $8.56M
- Enterprise Value
- $1.87M
- Total Cash (Recent Filing)
- $8.78M
- Total Debt (Recent Filing)
- $160.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.35
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.64
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Promising Phase 1 Efficacy
DA-1726 has generated clinically relevant early efficacy signals across liver fat and body weight, supporting its potential fit in liver-related cardiometabolic disease. If replicated in larger and longer studies, these results could strengthen the pipeline’s development rationale and partnering appeal.
Differentiated Preclinical Profile
The head-to-head study suggests DA-1726 may achieve weight loss through a differentiated metabolic mechanism involving glucagon-associated energy expenditure, FGF21 and thermogenesis. These findings could help distinguish the candidate scientifically, although clinical validation remains necessary.
Low Financial Leverage
Very low leverage reduces near-term solvency pressure and limits the burden of mandatory debt service while the company advances its clinical pipeline. This conservative capital structure provides more flexibility than a heavily indebted balance sheet, even though equity resources are declining.
Bears Say
Pre-revenue Operating Model
MTVA has no commercial revenue base to fund research, development or corporate costs, leaving value dependent on successful clinical execution and eventual commercialization. Persistent losses also mean the company cannot yet demonstrate a self-sustaining operating model or durable earnings power.
Sustained Cash Burn
Ongoing negative operating and free cash flow shows that current activities consume capital rather than generate internal funding. Continued development spending without revenue increases the likelihood that MTVA will need additional financing, making funding availability an important execution constraint.
Shrinking Equity Cushion
The sharp reduction in shareholders’ equity indicates that losses are depleting the company’s capital base despite low debt. A thinner equity cushion reduces financial resilience and can increase reliance on future capital raising, potentially constraining strategy and creating dilution risk.
MetaVia News
MetaVia reports ‘positive’ DA-1726 data at Obesity Week 2026
MetaVia (MTVA) announced positive preclinical data from a head-to-head study comparing DA-1726, a novel GLP-1 /glucagon dual-receptor agonist, with retatrutide, a triple GLP-1R/GIPR/GCGR agonist. The findings, presented on November 14,
Analyst Maintains Buy Rating on MetaVia (MTVA) with Unchanged $8 Price Target, Citing Strong Early Obesity Data for DA-1726
Maxim Group analyst Jason McCarthy maintained a Buy rating on MetaVia yesterday and set a price target of $8.00. Jason McCarthy has given his Buy rating due to a combination
MetaVia reports results from DA-1726-derived radioactivity study
MetaVia (MTVA) announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body following subcutaneous administration, with broad tissue distribution
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
What is MetaVia’s market cap?
When is MetaVia’s upcoming earnings report date?
How were MetaVia’s earnings last quarter?
Is MetaVia overvalued?
Does MetaVia pay dividends?
What is MetaVia’s EPS estimate?
How many shares outstanding does MetaVia have?
What happened to MetaVia’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MetaVia?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MetaVia
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hyung Heon Kim
- Employees
- 8
- Website
- www.metaviatx.com
- Address
- 545 Concord Avenue, Cambridge, MA, 02138, US
MetaVia (MTVA) Earnings & Revenues
MTVA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 1 | 0 | 11 |













